Luteinizing hormone-releasing hormone analogues - the rationale for adjuvant use in premenopausal women with early breast cancer
1998

LHRH Analogues for Early Breast Cancer Treatment

Sample size: 228 publication Evidence: moderate

Author Information

Author(s): W Jonat

Primary Institution: Gynaecology and Obstetrics Clinic, University of Kiel

Hypothesis

Can luteinizing hormone-releasing hormone (LHRH) analogues like goserelin be effectively used as adjuvant therapy in premenopausal women with early breast cancer?

Conclusion

Goserelin shows potential as an effective adjuvant therapy for early breast cancer in premenopausal women with fewer side effects compared to standard chemotherapy.

Supporting Evidence

  • Goserelin has an objective response rate of 36.4% with a median response duration of 44 weeks.
  • Goserelin does not stimulate the ovaries and is unlikely to have detrimental effects on the endometrium.
  • Goserelin plus tamoxifen may be as effective as standard chemotherapy but with significantly less acute toxicity.

Takeaway

Goserelin is a medicine that helps treat early breast cancer in younger women by lowering hormone levels, and it might be safer than other treatments.

Methodology

Pooled data from 29 studies assessing the efficacy and safety of goserelin in premenopausal and perimenopausal women with advanced breast cancer.

Limitations

The long-term effects of goserelin on bone mineral density and cardiovascular events are still being evaluated.

Participant Demographics

Premenopausal and perimenopausal women with early breast cancer.

Statistical Information

P-Value

0.03

Statistical Significance

p=0.03

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication